- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
A new study by researchers at the University of Kentucky Cancer Nanotechnology Platform Partnership (Kentucky CNPP) shows promise for developing ultrastable RNA nanoparticles that may help treat cancer by regulating cell function and binding to tumors without harming surrounding tissue. This work, led by Peixuan Guo and Mark Evers, was published in the journal Nano Today.
The study uses RNA as a building block for the bottom-up fabrication of nanostructures. The researchers constructed ultrastable X-shaped RNA nanoparticles using re-engineered RNA fragments to carry up to four therapeutic and diagnostic modules. These RNA nanoparticles can include small interfering RNA (siRNA) for silencing genes, micro-RNA (miRNA) for regulating gene expression, RNA aptamers for targeting cancer cells, or RNA-based enzymes, also known as ribozymes, that can catalyze chemical reactions.
In their study, the investigators demonstrated that regulation of cellular functions progressively increased with the increasing number of functional modules in the nanoparticle. "RNA nanotechnology is an emerging field, but the instability and degradation of RNA nanoparticles have made many scientists flinch away from the research in RNA nanotechnology," Dr. Guo said. "We have addressed these issues, and now it is possible to produce RNA nanoparticles that are highly stable both chemically and thermodynamically in the test tube or in the body with great potential as therapeutic reagents."
The RNA nanoparticles displayed several favorable attributes: polyvalency, which allows simultaneous delivery of multiple functional molecules for achieving synergistic effects; modular design, which enables controlled self-assembly with defined structure; thermodynamic stability, which keeps the RNA nanoparticles intact in animal and human circulation systems where they exist at very low concentrations; and chemical stability, which makes the nanoparticles resistant to digestion by RNases, enzymes in blood that breakdown RNA.
About The National Cancer Institute (NCI)
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © The National Cancer Institute (NCI)If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
The intermediates in a chemical reaction photographed 'red-handed' Researchers at the UPV/EHU-University of the Basque Country have for the first time succeeded in imaging all the steps in a complex organic reaction and have resolved the mechanisms that explain it May 4th, 2016
Nuclear pores captured on film: Using an ultra fast-scanning atomic force microscope, researchers from the University of Basel have filmed 'living' nuclear pore complexes at work for the first time May 3rd, 2016